Compare DraftKings Inc (DKNG) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DraftKings Inc vs Pfizer Inc — how do they compare? DraftKings Inc trades at $19.9 (market cap $9.51B), while Pfizer Inc trades at $27.74 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 16.8× DraftKings Inc's market cap, and Pfizer Inc pays a 6.14% dividend while DraftKings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DraftKings Inc for 55 Days and Pfizer Inc for 158 Days on average.
| DKNG | PFE | |
|---|---|---|
Market Cap | $9.51B | $159.59B |
Volume | 11,829,779 | 30,937,010 |
Sector | Consumer Cyclical | Health |
52-Week High | $36.24 | $29.02 |
52-Week Low | $18.59 | $23.67 |
Typical Hold Time | 55 Days | 158 Days |
Enterprise Value | $10.44B | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DraftKings (DKNG) trades at $19.87, near its 52-week low, with a bearish technical outlook despite strong analyst support. The company achieved profitability in 2025 with $6.05B revenue and positive net income of $3.71M, though recent quarters show earnings misses. Operating cash flow improved to $663M in 2025, but high valuation multiples (P/E 246.33) and negative ROE (-22.12%) highlight risks. Recent news focuses on prediction market expansion and NFL season performance.
The stock faces near-term pressure from technical weakness and earnings volatility, but long-term growth drivers in sports betting and predictions remain intact. Wall Street maintains strong bullish sentiment with a $33.13 price target, though investors should weigh high valuation against execution risks and competitive threats in the evolving gaming landscape.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
